CareDx, Inc. (CDNA) Major Shareholder Neil Gagnon Buys 6,496 Shares
CareDx, Inc. (NASDAQ:CDNA) major shareholder Neil Gagnon bought 6,496 shares of the stock in a transaction on Thursday, September 7th. The shares were bought at an average cost of $3.05 per share, with a total value of $19,812.80. Following the purchase, the insider now owns 916,546 shares of the company’s stock, valued at $2,795,465.30. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Neil Gagnon also recently made the following trade(s):
- On Monday, August 28th, Neil Gagnon bought 21,448 shares of CareDx stock. The shares were bought at an average cost of $2.77 per share, with a total value of $59,410.96.
- On Friday, August 25th, Neil Gagnon bought 35,119 shares of CareDx stock. The shares were bought at an average cost of $2.92 per share, with a total value of $102,547.48.
- On Monday, July 24th, Neil Gagnon bought 1,486 shares of CareDx stock. The shares were bought at an average cost of $1.23 per share, with a total value of $1,827.78.
- On Thursday, June 29th, Neil Gagnon bought 1,808 shares of CareDx stock. The shares were bought at an average cost of $1.11 per share, with a total value of $2,006.88.
- On Friday, June 23rd, Neil Gagnon bought 63,120 shares of CareDx stock. The shares were bought at an average cost of $1.10 per share, with a total value of $69,432.00.
CareDx, Inc. (NASDAQ CDNA) traded up 0.34% on Friday, hitting $2.98. 267,268 shares of the stock traded hands. The stock’s market cap is $67.17 million. CareDx, Inc. has a 12-month low of $0.76 and a 12-month high of $4.66. The firm’s 50-day moving average price is $1.91 and its 200-day moving average price is $1.48.
CareDx (NASDAQ:CDNA) last issued its earnings results on Thursday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.19). CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. The business had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $11.87 million. On average, equities research analysts anticipate that CareDx, Inc. will post ($0.82) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/08/caredx-inc-cdna-major-shareholder-neil-gagnon-buys-6496-shares.html.
Several large investors have recently modified their holdings of CDNA. Gagnon Securities LLC grew its holdings in shares of CareDx by 12.8% during the 1st quarter. Gagnon Securities LLC now owns 2,026,338 shares of the company’s stock worth $2,837,000 after purchasing an additional 230,494 shares during the period. Royce & Associates LP grew its holdings in shares of CareDx by 39.3% during the 2nd quarter. Royce & Associates LP now owns 733,287 shares of the company’s stock worth $814,000 after purchasing an additional 206,815 shares during the period. Finally, Stonepine Capital Management LLC purchased a new stake in shares of CareDx during the 2nd quarter worth about $212,000. Institutional investors and hedge funds own 29.15% of the company’s stock.
Several research analysts have weighed in on the stock. Zacks Investment Research raised shares of CareDx from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. ValuEngine lowered shares of CareDx from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.